BRIEF-Aptose Prioritizes Development Of CG'806 First-in Class FLT3 ...

Tag » Apto-cg-806-01

• A Study Of CG-806 In Patients With Relapsed Or Refractory CLL/SLL ...

• A Study Of CG-806 In Patients With Relapsed Or Refractory AML Or ...

• Aptose Doses First CLL Patient In Phase 1 Study Of CG-806 And ...

• Luxeptinib For CLL & NHL - Aptose Biosciences Inc.

• Aptose Presents New Preclinical Data On CG-806 And APTO-253

• Aptose Presents Early Phase 1a/b CG-806 Clinical Findings

• FDA Allows Human Trials Of Aptose's CG-806 Oral Compound For AML

• CG'806, A First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits ...

• Luxeptinib - Aptose Biosciences/CrystalGenomics - AdisInsight

• CG-806 For Relapsed Or Refractory CLL/SLL Or Non-Hodgkin's ...

• 18281-Waldenström Macroglobulinemia-NA-596

• A Study Of CG-806 In Patients With Relapsed Or Refractory CLL/SLL ...

• Aptose Prioritizes Development Of CG'806 First-in Class FLT3/BTK ...